Pages Menu
TwitterRssFacebook
ISSN (Online): 2454-1680

OncoExpert

INTERNATIONAL JOURNAL OF INTEGRATED ONCOLOGY

An Official Publication Of Society Of Pharmaceutical Science & Research
Categories Menu

Volume 1 (2015) - Issue 1, Jan-Jun

Review Articles

 
Title
Views
PDF
Cited
1.

CANCER CHRONOTHERAPY: THE RIGHT TIME TO HIT!

Chronomodulated therapy or chronotherapy has gained popularity, beyond a fancy term, as a novel and logical method to exploit the best, by administering anti-cancer treatment at an optimal timing according to circadian rhythms of their anti-cancer action and/or repair mechanism of cancer & normal cells. Understanding of chronobiology and the results of clinical studies back up this new concept. Chronotherapy seems to have all the potential to become tomorrow’s accepted, refined oncology practice without adding much to the cost of existing...

Ashok Kumar Chauhan, Yashpal Verma and Ramesh Sabharwal

Dr Yashpal Verma, Medical Officer, Department of Radiotherapy, Post graduate institute of medical sciences, Rohtak (INDIA)

DOI:

1-7

1116

723

0

2.

INTENSITY MODULATED RADIATION THERAPY: OVERVIEW OF JOURNEY FROM CONVENTIONAL TO DASSIM-RT

Intensity modulated radiation therapy (IMRT) is a technique to deliver a highly conformal radiation dose distribution, that too with wide spectrum ranging from conventional IMRT, through Volumetric Modulated Arc Therapy (VMAT) to most advanced form called Dense Angularly Sampled and Sparse Intensity Modulated Radiation Therapy (DASSIM-RT). The article intends to overview the current status of the technology....

Yogesh Kumar, Ashok Kumar Chauhan, Nagappan Balasubramanian, Narayan Parshad Patel and Yashpal Verma

Yogesh Kumar, Physicist, Department of Radiotherapy, Post-graduate institute of medical sciences, Rohtak (INDIA) - 124001. Mobile: +91-9416357357

DOI:

8-13

1211

498

0

3.

ROLE OF COENZYME Q10 IN CURRENT ONCOLOGY PRACTICE: SUBSTANCE OR SHADOW!

CoQ10 tissue levels. CoQ10 therapy has no serious side effects in humans and new formulations have been developed that increase CoQ10 absorption and tissue distribution. CoQ10 has a role in carcinoma breast, cervix, lung, prostate, melanoma, cancer chemotherapy and cancer related fatigue. Future trends involving CoQ10 in many cancers needs more clinical trials for better understanding of CoQ10 efficacy.. Oral CoQ10 administration can correct CoQ10 deficiency since it increases CoQ10 tissue levels. CoQ10 therapy has no serious side effects in humans and new formulations have been developed that increase CoQ10 absorption and tissue distribution. CoQ10 has a role in carcinoma breast, cervix, lung, prostate, melanoma, cancer chemotherapy and cancer related fatigue. Future trends involving CoQ10 in many cancers needs more clinical trials for better understanding of CoQ10...

Abhishek Soni, Monica Verma, Sumeet Aggarwal, Vivek Kaushal and Yashpal Verma

Dr Abhishek Soni, Senior Resident, Department of Radiotherapy, Post-graduate Institute Of Medical Sciences, Rohtak (INDIA) - 124001

DOI:

14-22

1214

904

0

4.

CHEMOTHERAPY INDUCED NEUROPATHY: PATHO-PHYSIOLOGY AND POSSIBLE NEURO-PROTECTIVE STRATEGIES

With the advent of effective and intensive chemotherapy, we are able to achieve better response rates as well as improved survival but the side effects remain a constraint. This article intends to discuss one of the side effects of chemotherapy i.e. neuropathy; culprit agents, mechanism and therapeutic strategies to manage it.

Ramesh Sabharwal, Ravi Uniyal, Yashpal Verma and Mukesh Kumar Bharti

Dr. Ramesh Sabharwal Medical Officer, General Hospital, Department of Health, Kurukshetra, Haryana (India)

DOI:

23-30

1332

490

0

Case study

 
Title
Views
PDF
Cited
5.

UNUSUAL PRESENTATION OF NON-HODGKIN LYMPHOMA: VULVA GROWTH AND BREAST MASS IN THE SAME PATIENT

Primary involvement of vulva or breast by non-hodgkin lymphoma (NHL) is known to occur uncommonly. Only 24 cases of NHL vulva and around 250 cases of NHL breast alone have been reported, so far; but none with simultaneous involvement of the two sites together. We report the first case having both sites involved in a 35 year old Indian female.

Yashpal Verma, Ashok K. Chauhan, Ramesh Sabharwal and Jagjeet Singh

Dr. Yashpal Verma, Medical Officer, Department of Radiotherapy, University of Health Sciences, Rohtak (INDIA). Contact no. +91-9416125026

DOI:

31-34

1074

556

0

6.

PRIMARY NON-HODGKIN LYMPHOMA OF LIVER: AN UNUSUAL PRESENTATION AND REVIEW OF ITS MANAGEMENT.

 Primary Non-Hodgkin lymphoma (NHL) of liver is a very rare malignancy. Here, we report a case of 26 years old man who presented with right upper abdomen pain and lump, reduced appetite and progressive weakness of 4 month’s duration. Liver functions were deranged but serology was negative for viral markers and α Fetoprotein was within normal range. Ultrasonography and Computed Tomography scan of the abdomen revealed large nodule in right lobe of the liver. USG guided biopsy of liver mass and fluorescence in situ hybridization for CD markers established diagnosis of primary NHL of liver. Extensive investigations including X-ray of chest, whole-body positron-emission tomography scan and bone marrow biopsy showed no involve­ment of mediastinum, spleen, bone marrow or any other organ or lymph nodes significantly. Having B symptoms disease was staged IVB, the patient has been treated with 6 cycles of R-CHOP regimen (Rituximab/Cyclophosphamide–Doxorubicin–Vincristine–Prednisolone) followed by 2 courses of CHOP every three weekly. Response has been excellent and patient is asymptomatic as of now. This case highlights that primary hepatic lymphoma should be considered in the differential diagnosis of space-occupying liver lesions in presence of normal levels of...

Mukesh Kumar Bharti, Sudhakar Singh

Dr. Mukesh Kumar Bharti Assistant Professor, Dept of Radiotherapy & Oncology DMCH Laheriasarai, Darbhanga, Bihar

DOI:

35-39

875

525

0